Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy.

Toxins 2025 Vol.17(3)

Cecchella E, Bragazzi NL, Cotellessa F, Campanella W, Puce L, Marinelli L, Currà A, Schenone C, Mori L, Trompetto C

관련 도메인

Abstract

Stroke is a leading cause of long-term disability worldwide, often resulting in spasticity. Botulinum toxin injections have emerged as a cornerstone in the management of post-stroke spasticity. However, despite their clinical efficacy, maintaining long-term adherence to botulinum toxin therapy remains a significant challenge. This retrospective observational study analyzed 106 patients undergoing botulinum toxin therapy for post-stroke spasticity to identify the key factors influencing treatment continuation. The mean age of the cohort at the time of stroke was 57.7 years, with ischemic strokes accounting for 61.3% of cases and hemorrhagic strokes for 38.7%. A total of 61.3% of patients continued therapy, while 38.7% discontinued therapy due to a variety of reasons. The most common reasons included logistical barriers (43.9%) and comorbidities (36.6%), followed by perceived lack of benefit (24.4%) and clinical resolution (12.2%). Among those citing a lack of benefit, muscular fibrosis was a notable contributor. In the multivariable Cox regression analysis, logistical challenges, such as access to healthcare facilities and administrative difficulties, were associated with discontinuation (HR = 13.95, 95% CI: 5.57-34.94, < 0.001). Comorbidities also significantly increased the likelihood of discontinuation (HR = 3.51, 95% CI: 1.56-7.87, = 0.002), as did the lack of benefit (HR = 14.34, 95% CI: 5.65-36.38, < 0.001) and condition resolution (HR = 19.20, 95% CI: 5.58-66.02, < 0.001). In contrast, demographic and clinical factors, including age at the time of stroke, gender, stroke type, affected side, and baseline spasticity severity, did not significantly influence treatment continuation. These findings underscore the importance of addressing logistical barriers and mitigating the burden of comorbidities to enhance treatment adherence. A shift toward patient-centered approaches that integrate robust rehabilitation services and streamline healthcare accessibility is critical for optimizing outcomes.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 4
약물 Long-Term scispacy 1
질환 Post-Stroke Spasticity scispacy 1
질환 Stroke C0038454
Cerebrovascular accident
scispacy 1
질환 long-term disability scispacy 1
질환 spasticity C0026838
Muscle Spasticity
scispacy 1
질환 ischemic strokes C0948008
Ischemic stroke
scispacy 1
질환 hemorrhagic strokes C5234922
Hemorrhagic Stroke
scispacy 1
질환 muscular fibrosis scispacy 1
기타 Post-Stroke scispacy 1
기타 patients scispacy 1
기타 muscular scispacy 1

MeSH Terms

Humans; Muscle Spasticity; Middle Aged; Male; Female; Stroke; Retrospective Studies; Italy; Aged; Botulinum Toxins; Adult; Medication Adherence; Neuromuscular Agents

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문